Abivax H1FY26 Results: Loss expected at $1.08 per share
- Abivax reports H1 earnings on Sept 21; loss of $1.08/share expected
- Revenue forecast at $1.86 million for the period
- Shares rose 2.3% to $118.64 ahead of the release
- Positive pre-NDA FDA interaction for Obefazimod announced July 30
- Multiple analysts raised price targets between June and July 2026
*this image is generated using AI for illustrative purposes only.
Abivax Société Anonyme (NASDAQ: ABVX) will release its first-half earnings report after the closing bell on Monday, September 21.
Analysts expect the Paris-based company to report a loss of $1.08 per share on revenue of $1.86 million, according to Benzinga Pro data.
The stock closed at $118.64 on Friday, up 2.3% from the previous session. This movement follows the company’s announcement on July 30 of a positive pre-NDA interaction with the FDA for Obefazimod.
Analyst Revisions
Several analysts have revised their outlooks for Abivax in recent weeks, citing the regulatory progress and upcoming financial disclosure.
| Analyst | Firm | Rating | Price Target | Accuracy | Date |
|---|---|---|---|---|---|
| Allison Bratzel | Piper Sandler | Overweight | $175 | 73% | July 9, 2026 |
| Gregory Renza | Truist Securities | Buy | $155 | 63% | July 2, 2026 |
| Jason N. Butler | Citizens | Market Outperform | $187 | 72% | July 1, 2026 |
| Faisal Khurshid | Jefferies | Buy (Upgraded) | $158 | 75% | June 30, 2026 |
| David Nierengarten | Wedbush | Neutral | $110 | 80% | June 30, 2026 |
Piper Sandler analyst Allison Bratzel raised the price target from $165 to $175 on July 9, 2026, maintaining an Overweight rating. Truist Securities’ Gregory Renza increased his target from $135 to $155 on July 2, 2026, keeping a Buy rating.
Citizens analyst Jason N. Butler maintained a Market Outperform rating with a $187 target on July 1, 2026. Jefferies’ Faisal Khurshid upgraded the stock from Hold to Buy and boosted the target from $108 to $158 on June 30, 2026.
Wedbush’s David Nierengarten maintained a Neutral rating but raised the target from $90 to $110 on June 30, 2026.
What the Numbers Show
The divergence between the current share price ($118.64) and the consensus revenue estimate ($1.86 million) highlights the market’s valuation of Abivax based primarily on pipeline potential rather than near-term commercial scale. The positive FDA interaction serves as the key catalyst driving the upward revision in price targets across multiple firms.
How might the upcoming H1 earnings report impact the timeline for the FDA's final decision on Obefazimod's NDA?
What specific financial metrics in the earnings release could trigger further analyst upgrades or downgrades beyond the current consensus?
How will Abivax's cash burn rate and runway be affected if commercialization of Obefazimod is delayed past the expected timeline?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
